Literature DB >> 16808885

Telomerase inhibition impairs tumor growth in glioblastoma xenografts.

Maria Laura Falchetti1, Paolo Fiorenzo, Maria Patrizia Mongiardi, Giovanna Petrucci, Nicola Montano, Giulio Maira, Francesco Pierconti, Luigi Maria Larocca, Andrea Levi, Roberto Pallini.   

Abstract

Telomerase is a specialized DNA polymerase that is required to replicate the ends of linear chromosomes, the telomeres. The majority of human cancers express high levels of telomerase activity that is permissive for tumor growth because it provides cells with an extended proliferative potential. Additionally, telomerase exerts cell growth promoting functions and favors cell survival. Human glioblastoma multiforme (GBM) cells express high level of telomerase activity owing to the overexpression of human telomerase reverse transcriptase (hTERT), the limiting subunit of the enzyme. Here we used retroviral mediated RNA interference to dampen down telomerase activity in two distinct human GBM cell lines, U87MG and TB10. Substantial decrease of hTERT mRNA and telomerase activity had only minimal effects on telomere length maintenance, cell growth and survival in vitro. On the contrary, development of tumors upon subcutaneously grafting of U87MG and TB10 cells and intracranial implantation of U87MG cells in nude athymic mice was strongly reduced by telomerase inhibition.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16808885     DOI: 10.1179/016164106X116818

Source DB:  PubMed          Journal:  Neurol Res        ISSN: 0161-6412            Impact factor:   2.448


  8 in total

Review 1.  The TERT rs2736100 polymorphism and cancer risk: a meta-analysis based on 25 case-control studies.

Authors:  Peng Zou; Aihua Gu; Guixiang Ji; Lin Zhao; Peng Zhao; Ailin Lu
Journal:  BMC Cancer       Date:  2012-01-05       Impact factor: 4.430

2.  Lonafarnib (SCH66336) improves the activity of temozolomide and radiation for orthotopic malignant gliomas.

Authors:  Deviney Chaponis; Jessica W Barnes; Jamie L Dellagatta; Santosh Kesari; Eva Fast; Claire Sauvageot; Dipak Panagrahy; Emily R Greene; Naren Ramakrishna; Patrick Y Wen; Andrew L Kung; Charles Stiles; Mark W Kieran
Journal:  J Neurooncol       Date:  2011-01-19       Impact factor: 4.130

3.  Combination of hTERT knockdown and IFN-gamma treatment inhibited angiogenesis and tumor progression in glioblastoma.

Authors:  Joseph George; Naren L Banik; Swapan K Ray
Journal:  Clin Cancer Res       Date:  2009-11-24       Impact factor: 12.531

4.  Intracranial stereotaxic cannulation for development of orthotopic glioblastoma allograft in Sprague-Dawley rats and histoimmunopathological characterization of the brain tumor.

Authors:  Surajit Karmakar; M Foster Olive; Naren L Banik; Swapan K Ray
Journal:  Neurochem Res       Date:  2007-08-15       Impact factor: 3.996

5.  An Updated and Comprehensive Meta-Analysis of Association Between Seven Hot Loci Polymorphisms from Eight GWAS and Glioma Risk.

Authors:  Qiang Wu; Yanyan Peng; Xiaotao Zhao
Journal:  Mol Neurobiol       Date:  2015-08-05       Impact factor: 5.590

6.  Variants in the CDKN2B and RTEL1 regions are associated with high-grade glioma susceptibility.

Authors:  Margaret Wrensch; Robert B Jenkins; Jeffrey S Chang; Ru-Fang Yeh; Yuanyuan Xiao; Paul A Decker; Karla V Ballman; Mitchel Berger; Jan C Buckner; Susan Chang; Caterina Giannini; Chandralekha Halder; Thomas M Kollmeyer; Matthew L Kosel; Daniel H LaChance; Lucie McCoy; Brian P O'Neill; Joe Patoka; Alexander R Pico; Michael Prados; Charles Quesenberry; Terri Rice; Amanda L Rynearson; Ivan Smirnov; Tarik Tihan; Joe Wiemels; Ping Yang; John K Wiencke
Journal:  Nat Genet       Date:  2009-07-05       Impact factor: 38.330

7.  Suramin increased telomerase activity in the c6 glioma/wistar experimental brain tumor model.

Authors:  Mine Ergüven; Ayhan Bilir; Tuncay Altug; Fadime Aktar; Nuriye Akev
Journal:  Int J Biomed Sci       Date:  2007-06

8.  PinX1-siRNA/mPEG-PEI-SPION combined with doxorubicin enhances the inhibition of glioma growth.

Authors:  Ling Long; Weiwei Wang; Xia-Dong Cai; DU Cheng; Xintao Shuai; Ying Peng
Journal:  Exp Ther Med       Date:  2014-02-26       Impact factor: 2.447

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.